OBJECTIVE: To report a single institution experience in surgical stage I-II serous endometrial cancer using combined carboplatin/paclitaxel and intravaginal radiation (IVRT). METHODS: Between 10/00 and 12/06, 25 stage I-II patients with serous endometrial cancer were treated at our institution with surgery, postoperative IVRT, and concurrent chemotherapy (CT). RESULTS: The mean age was 67 years old (range, 53-80 years). Surgery consisted of hysterectomy (TAH/BSO, 64%, LAVH/BSO, 36%), peritoneal washing, omental biopsy, and pelvic lymph-node dissection (median 14 nodes). Para-aortic node sampling was done in 88% (median, 6). IVRT median dose was 21 Gy (range, 18-21 Gy, in 3 fractions) and concurrent CT consisted of carboplatin to AUC=5 and taxol to 175 mg/m(2) given every 3 weeks for 6 cycles. CT was well tolerated with 22/25 (88%) receiving 6 cycles. Three patients received <or=5 cycles; 2 owing to physician preference (3 and 4 cycles) and 1 owing to toxicity (5 cycles). Only 1 patient (4%) had grade 3 toxicity (abscess). Grade 2 neurotoxicity was seen in 5 patients (20%). All patients finished their IVRT as scheduled, and there was no grade 3 toxicity. With a median follow-up of 30 months, the 5-year progression-free and overall survival rate was 88%. None of the patients developed vaginal recurrence. CONCLUSIONS: Based on this study, surgical staging followed by IVRT and carboplatin/paclitaxel is well tolerated and effective in stage I-II serous endometrial cancer. Confirmation of these results on a larger number of patients with longer follow-up is still needed.
OBJECTIVE: To report a single institution experience in surgical stage I-II serous endometrial cancer using combined carboplatin/paclitaxel and intravaginal radiation (IVRT). METHODS: Between 10/00 and 12/06, 25 stage I-II patients with serous endometrial cancer were treated at our institution with surgery, postoperative IVRT, and concurrent chemotherapy (CT). RESULTS: The mean age was 67 years old (range, 53-80 years). Surgery consisted of hysterectomy (TAH/BSO, 64%, LAVH/BSO, 36%), peritoneal washing, omental biopsy, and pelvic lymph-node dissection (median 14 nodes). Para-aortic node sampling was done in 88% (median, 6). IVRT median dose was 21 Gy (range, 18-21 Gy, in 3 fractions) and concurrent CT consisted of carboplatin to AUC=5 and taxol to 175 mg/m(2) given every 3 weeks for 6 cycles. CT was well tolerated with 22/25 (88%) receiving 6 cycles. Three patients received <or=5 cycles; 2 owing to physician preference (3 and 4 cycles) and 1 owing to toxicity (5 cycles). Only 1 patient (4%) had grade 3 toxicity (abscess). Grade 2 neurotoxicity was seen in 5 patients (20%). All patients finished their IVRT as scheduled, and there was no grade 3 toxicity. With a median follow-up of 30 months, the 5-year progression-free and overall survival rate was 88%. None of the patients developed vaginal recurrence. CONCLUSIONS: Based on this study, surgical staging followed by IVRT and carboplatin/paclitaxel is well tolerated and effective in stage I-II serous endometrial cancer. Confirmation of these results on a larger number of patients with longer follow-up is still needed.
Authors: G T Bozas; A Bamias; E Kastritis; A Rodolakis; G Vlahos; C A Papadimitriou; S Markaki; M A Dimopoulos Journal: Eur J Gynaecol Oncol Date: 2005 Impact factor: 0.196
Authors: Michael G Kelly; David M O'malley; Pei Hui; Jessica McAlpine; Herbert Yu; Thomas J Rutherford; Masoud Azodi; Peter E Schwartz Journal: Gynecol Oncol Date: 2005-09 Impact factor: 5.482
Authors: F D Cirisano; S J Robboy; R K Dodge; R C Bentley; H R Krigman; I S Synan; J T Soper; D L Clarke-Pearson Journal: Gynecol Oncol Date: 2000-04 Impact factor: 5.482
Authors: Gregory Sutton; Janice H Axelrod; Brian N Bundy; Tapan Roy; Howard Homesley; Roger B Lee; Paola A Gehrig; Richard Zaino Journal: Gynecol Oncol Date: 2005-10-05 Impact factor: 5.482
Authors: G Larry Maxwell; G V R Chandramouli; Lou Dainty; Tracy J Litzi; Andrew Berchuck; J Carl Barrett; John I Risinger Journal: Clin Cancer Res Date: 2005-06-01 Impact factor: 12.531
Authors: Kristin K Zorn; Tomas Bonome; Lisa Gangi; Gadisetti V R Chandramouli; Christopher S Awtrey; Ginger J Gardner; J Carl Barrett; Jeff Boyd; Michael J Birrer Journal: Clin Cancer Res Date: 2005-09-15 Impact factor: 12.531
Authors: William T Creasman; Matthew F Kohler; Franco Odicino; Patrick Maisonneuve; Peter Boyle Journal: Gynecol Oncol Date: 2004-12 Impact factor: 5.482
Authors: Laura J Havrilesky; Angeles Alvarez Secord; Victoria Bae-Jump; Tina Ayeni; Brian Calingaert; Daniel L Clarke-Pearson; Andrew Berchuck; Paola A Gehrig Journal: Gynecol Oncol Date: 2007-03-13 Impact factor: 5.482
Authors: Melissa Rasar Young; Susan A Higgins; Elena Ratner; James B Yu; Sheida Mani; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Peter E Schwartz; Shari Damast Journal: Int J Gynecol Cancer Date: 2015-03 Impact factor: 3.437
Authors: Daniela Matei; Virginia Filiaci; Marcus E Randall; David Mutch; Margaret M Steinhoff; Paul A DiSilvestro; Katherine M Moxley; Yong M Kim; Matthew A Powell; David M O'Malley; Nick M Spirtos; William Small; Krishnansu S Tewari; William E Richards; John Nakayama; Ursula A Matulonis; Helen Q Huang; David S Miller Journal: N Engl J Med Date: 2019-06-13 Impact factor: 91.245
Authors: Harriet Belding Eldredge-Hindy; Gary Eastwick; Pramila Rani Anne; Norman G Rosenblum; Russell J Schilder; Raffi Chalian; Allison M Zibelli; Christine H Kim; Robert Den Journal: J Contemp Brachytherapy Date: 2014-09-05
Authors: Shari Damast; Susan A Higgins; Elena Ratner; Maria C De Leon; Sheida Mani; Dan-Arin Silasi; Masoud Azodi; Alessandro Santin; Thomas Rutherford; Peter E Schwartz Journal: J Contemp Brachytherapy Date: 2015-01-26